ResMed has announced the discontinuation of its Astral ventilator portfolio, effective September 14, 2026, according to a customer notice shared with Bemes. The decision affects the Astral 100, product code 27001, and Astral 150, product code 27003.

For patients, caregivers, and equipment providers, the announcement raises practical questions about continued use, replacement parts, maintenance, and future equipment availability. ResMed’s notice outlines a planned support period through December 31, 2034, while emphasizing that existing safety correction instructions remain in effect.

Why is ResMed discontinuing the Astral ventilators?

ResMed attributes the decision to ongoing supply constraints affecting critical electronic components. After reviewing the long-term availability of those components, the company determined that continued manufacturing faced significant challenges.

According to the notice, discontinuing the portfolio allows ResMed to prioritize available components and resources for existing patients and continuity of care.

Can customers still purchase an Astral 100 or Astral 150?

ResMed states that Astral ventilators are no longer available for general commercial purchase. Any remaining finished units within its distribution channels will be allocated through controlled processes to support continuity of care and the ongoing Field Safety Corrective Action, subject to local inventory availability.

This means customers should not assume that remaining manufacturer inventory is available for routine orders. Questions about existing orders, contracts, tenders, or commercial commitments should be directed to a local ResMed representative.

The notice does not establish the availability of individual units held by independent equipment sellers.

How long will parts and service support continue?

ResMed plans to provide Astral accessories, spare parts, service, and maintenance support through December 31, 2034.

That date is a planned support endpoint, subject to several conditions:

• Applicable regulatory requirements
• Component and supply availability
• Service capacity
• Local customer obligations

ResMed says it will make sustained and reasonable efforts to maintain support throughout this period. However, the announcement should not be interpreted as an unconditional guarantee that every part or service will remain available until that date. It also does not extend an individual device’s warranty.

For equipment owners and fleet managers, this is a useful time to review service records, upcoming maintenance, accessory needs, and longer-term replacement plans with their equipment provider.

Should patients stop using their Astral ventilator?

The discontinuation notice states that patients may continue using their devices in accordance with applicable clinical guidance unless their treating clinician advises otherwise.

Patients and caregivers should not stop prescribed ventilation or change equipment or settings solely because of this announcement. Questions about continued use or a future transition should be discussed with the treating clinical team and equipment provider.

The FDA’s Astral ventilator correction notice also advises patients to continue therapy unless otherwise directed by their treating clinician.

Does this change the Astral safety correction?

No. ResMed explicitly states that the Field Safety Corrective Action, or FSCA, is separate from the product discontinuation decision and remains active and unchanged.

For affected customers and patients, the lifecycle announcement does not replace existing safety instructions, patient guidance, or ResMed’s corrective action commitments. Those instructions must still be followed.

Customers outside the scope of the FSCA do not need to take FSCA-related action simply because they received the discontinuation notice. Anyone uncertain whether their device is affected should contact their equipment provider or ResMed for confirmation.

What should equipment providers do next?

Providers managing Astral fleets should begin planning around the announced lifecycle change while supporting patients already using these devices. Practical next steps include reviewing maintenance schedules, confirming applicable corrective actions, and discussing parts and service availability with ResMed.

Future equipment transitions should be coordinated with the treating clinical team. Selecting another ventilator requires consideration of the patient’s prescribed therapy, circuit requirements, accessories, and caregiver training.

ResMed says the Astral decision is specific to this portfolio. The company’s notice reiterates its commitment to home-based respiratory care and continued investment in non-invasive ventilation and related solutions.

For questions about your existing Astral equipment or service needs, contact the Bemes team at 866-490-1609 or sales@bemeseast.com. Availability and the scope of any service should be confirmed for your specific unit.

Source: ResMed customer lifecycle notice supplied to Bemes, signed by Sean Redmond, Director, Breathing Health, announcing an effective discontinuation date of September 14, 2026. The discontinuation and planned support dates above are attributed to that notice.

Image: AI-edited studio setting based on an authentic Astral 150 product photograph from ResMed.